Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nuvation Bio (NUVB)
NYSE:NUVB
Nuvation Bio (NUVB) Stock Price & Analysis
151 Followers
NUVB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.95 - $4.16
Previous Close$3
Volume1.92M
Average Volume (3M)1.60M
Market Cap
$746.01M
Enterprise Value$152.56M
Total Cash (Recent Filing)$596.98M
Total Debt (Recent Filing)$3.53M
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Aug 01, 2024EPS Estimate
-$0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding247,170,648
10 Day Avg. Volume1,398,508
30 Day Avg. Volume1,603,508
Standard Deviation0.21
R-Squared0.11
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.25
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-12.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.74
Forecast
1Y Price Target
$6.60Price Target Upside120.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Nuvation Bio News
PremiumCompany Announcements
Nuvation Bio Expands and Refreshes Leadership with AcquisitionBulls Say, Bears Say
Bulls Say
Clinical Trial SuccessTaletrectinib at 600mg QD demonstrated a 91% confirmed ORR (cORR)—78.6% of responders had at least a 24-month duration of response—and a mPFS that was not yet reached in TKI-naive ROS1+ NSCLC patients.
Financial PositionNuvation Bio ended 1Q24 with $597M in cash, cash equivalents, and marketable securities, which should provide an operational runway through 2028.
Regulatory ApprovalTaletrectinib has recently been granted orphan drug designation by the FDA for the treatment of ROS1, NTRK, ALK, LTK, ACK1, or DDR1-positive NSCLC.
Bears Say
Clinical RisksRisks include, but are not limited to: negative clinical proof-of-concept for either NUV-868 or any of the other pipeline programs.
Drug LaunchThe drug repotrectinib has seen a slower-than-expected launch likely due to its safety profile, which showed higher neurological adverse effects compared to crizotinib.
Regulatory ApprovalThere could be some delay in obtaining US approval because both TRUST studies are single-arm, which may require a P3 randomized confirmatory trial.
---
Ownership Overview
43.77% Insiders
18.14% Mutual Funds
9.27% Other Institutional Investors
28.83% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NUVB FAQ
What was Nuvation Bio’s price range in the past 12 months?
Nuvation Bio lowest stock price was $0.95 and its highest was $4.16 in the past 12 months.
What is Nuvation Bio’s market cap?
Currently, no data Available
When is Nuvation Bio’s upcoming earnings report date?
Nuvation Bio’s upcoming earnings report date is Aug 01, 2024 which is in 10 days.
How were Nuvation Bio’s earnings last quarter?
Nuvation Bio released its earnings results on May 14, 2024. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.092 by $0.022.
Is Nuvation Bio overvalued?
According to Wall Street analysts Nuvation Bio’s price is currently Undervalued.
Does Nuvation Bio pay dividends?
Nuvation Bio does not currently pay dividends.
What is Nuvation Bio’s EPS estimate?
Nuvation Bio’s EPS estimate is -$0.06.
How many shares outstanding does Nuvation Bio have?
Nuvation Bio has 247,668,610 shares outstanding.
What happened to Nuvation Bio’s price movement after its last earnings report?
Nuvation Bio reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.092. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Nuvation Bio?
Among the largest hedge funds holding Nuvation Bio’s share is Omega Fund Management, LLC. It holds Nuvation Bio’s shares valued at 51M.
---
Nuvation Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.60 (120.00% Upside)
$6.60 (120.00% Upside)
Blogger Sentiment
Bullish
NUVB Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 988.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.8%
Last 30 Days ▲ 24.3%
Last 30 Days ▲ 24.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
57.06%
12-Months-Change
Fundamentals
Return on Equity
-11.15%
Trailing 12-Months
Asset Growth
-6.69%
Trailing 12-Months
Company Description
Nuvation Bio
Panacea Acquisition Corp is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
---
NUVB Stock 12 Month Forecast
Average Price Target
$6.60
▲(120.00% Upside)
Technical Analysis
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Editas Medicine
―
Sangamo Biosciences
―
Best Analysts Covering NUVB
1 Year
1 Year Success Rate
6/10 ratings generated profit
1 Year Average Return
+26.29%
reiterated a buy rating 2 months ago
Copying Gregory Renza's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +26.29% per trade.
---